Glaxo Wellcome flu drug setback
15 Jan 2000
The US Food and Drug Administration has refused to recommend Glaxo Wellcome's influenza treatment, Relenza, for approval. The Antiviral Drugs Advisory Committee expressed reservations about the drug's efficacy, the company says. Relenza is the first in a new class of `flu drugs.
